Vigamox for cats. Vigamox drops for bacterial eye inflammation
Instructions for use
Active ingredients
Release form
Compound
Active ingredient: Moxifloxacin Excipients: sodium chloride, boric acid, hydrochloric acid and/or sodium hydroxide (to adjust pH), purified water. Concentration active substance(mg): 5 mg
Pharmacological effect
Moxifloxacin - fluoroquinolone antibacterial drug IV generation, has a bactericidal effect. Is active in relation to wide range gram-positive and gram-negative microorganisms, anaerobic, acid-fast and atypical bacteria. The mechanism of action is associated with inhibition of topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an enzyme involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme involved in the cleavage of chromosomal DNA during bacterial cell division. There is no cross-resistance with macrolides, aminoglycosides and tetracyclines. The development of cross-resistance between systemically administered moxifloxacin and other fluoroquinolones has been reported. Moxifloxacin is active against most strains of microorganisms (both in vitro and in vivo): Gram-positive bacteria: Corynebacterium spp., including Corynebacterium diphtheriae; Micrococcus luteus (including strains insensitive to erythromycin, gentamicin, tetracycline and/or trimethoprim); Staphylococcus aureus(including strains insensitive to methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim); Staphylococcus epidermidis (including strains insensitive to methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim); Staphylococcus haemolyticus(including strains insensitive to methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim); Staphylococcus hominis (including strains insensitive to methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim); Staphylococcus warneri (including strains insensitive to erythromycin); Streptococcus mitis (including strains insensitive to penicillin, erythromycin, tetracycline and/or trimethoprim); Streptococcus pneumoniae (including strains insensitive to penicillin, erythromycin, gentamicin, tetracycline and/or trimethoprim); Streptococcus viridans group (including strains insensitive to penicillin, erythromycin, tetracycline and/or trimethoprim). Gram-negative bacteria: Acinetobacler Iwoffii; Haemophilus influenzae (including strains insensitive to ampicillin); Haemophilus parainfluenzae; Klebsiella spp. Other microorganisms: Chlamydia trachomatis. Moxifloxacin is effective in vitro against most of the microorganisms listed below, but clinical significance this data is unknown: Gram-positive bacteria: Listeria monocytogenes; Staphylococcus saprophyticus; Streptococcus agalactiae; Streptococcus mitis; Streptococcus pyogenes; Streptococcus groups C, G, F; Gram-negative bacteria: Acinetobacler baumannii; Acinetobacter calcoaceticus; Citrobacter freundii; Citrobacter koseri; Enterobacter aerogenes; Enterobacter cloacae; Escherichia coli; Klebsiella oxytoca; Klebsiella pneumoniae; Moraxella catarrhalis; Morganella morganii; Neisseria gonorrhoeae; Proteus mirabilis; Proteus vulgaris; Pseudomonas stutzeri; Anaerobic microorganisms: Clostridium perfringens; Fusobacterium spp.; Prevotella spp.; Propionibacterium acnes. Other organisms: Chlamydia pneumoniae; Legionella pneumophila; Mycobacterium avium; Mycobacterium marinum; Mycoplasma pneumoniae.
Pharmacokinetics
At local application systemic absorption of moxifloxacin occurs: Cmax is 2.7 ng/ml, AUC value is 45 ng×h/ml. These values are approximately 1600 times and 1000 times less than the Cmax and AUC after a therapeutic dose of moxifloxacin 400 mg orally. T1/2 of moxifloxacin from plasma is about 13 hours.
Indications
Bacterial conjunctivitis caused by microorganisms sensitive to moxifloxacin.
Contraindications
Children's and adolescence up to 1 year. Pregnancy. Lactation (breastfeeding period). Hypersensitivity to any of the components of the drug or to other quinolones.
Precautionary measures
Use during pregnancy and breastfeeding
There is no sufficient experience with the use of the drug during pregnancy and lactation. Use of the drug during pregnancy (FDA category C) is possible only if the expected healing effect for mother exceeds potential risk for the fetus and child. Vigamox can pass into breast milk, and therefore breastfeeding should be discontinued during treatment with the drug. Teratogenicity In preclinical studies in animals, moxifloxacin did not have a teratogenic effect at doses of 500 mg/kg/day (which is approximately 21,700 times higher than the recommended daily dose for humans). However, there was a slight decrease in fetal body weight and delayed development of the musculoskeletal system. At a dose of 100 mg/kg/day, an increase in the incidence of decreased growth in newborns was noted.
Directions for use and doses
Locally. Adults and children over 1 year of age: instill 1 drop into the affected eye 3 times a day. Usually, improvement occurs after 5 days and treatment should be continued for the next 2-3 days. If the condition does not improve after 5 days, the question of the correctness of the diagnosis and/or prescribed treatment should be raised. The duration of treatment depends on the severity of the condition and the clinical and bacteriological course of the disease.
Side effects
Local. In 1-10% of cases - pain, irritation and itching in the eye, dry eye syndrome, conjunctival hyperemia, eye hyperemia. In 0.1-1% of cases - a defect in the corneal epithelium, punctate keratitis, subconjunctival hemorrhage, conjunctivitis, swelling of the eye, discomfort in the eyes, blurred vision, decreased visual acuity, erythema of the eyelids, unusual sensations in the eye. Systemic. In 1-10% of cases - dysgeusia. In 0.1-1% of cases - headache, paresthesia, decreased blood hemoglobin, discomfort in the nose, pharyngolaryngeal pain, sensation foreign body in the throat, vomiting, increased levels of ALT and GGT. Post-marketing experience (frequency unknown): Local: endophthalmitis, ulcerative keratitis, corneal erosion, formation of corneal defects, increased intraocular pressure, corneal opacities, corneal infiltrates, deposits on the cornea, allergic reactions of the eye, keratitis, corneal edema, photophobia, blepharitis, eyelid edema, increased lacrimation, discharge from the eyes, sensation of a foreign body in the eye. Systemic: palpitations, dizziness, shortness of breath, nausea, erythema, rash, itching skin, hypersensitivity. Occurrence allergic reaction requires discontinuation of the drug! In patients using systemic quinolone drugs, including moxifloxacin, hypersensitivity reactions (anaphylaxis) were observed, including immediately after taking the first dose - collapse, loss of consciousness, Quincke's edema, obstruction respiratory tract, shortness of breath, itching, rash.
Overdose
If excess amounts of the drug get into your eyes, it is recommended to rinse your eyes with warm water.
Interaction with other drugs
The interaction of topically administered moxifloxacin with other drugs has not been studied. Data for oral administration are known. dosage form moxifloxacin: no clinically significant effects noted drug interactions(unlike other fluoroquinolone drugs) with theophylline, warfarin, digoxin, oral contraceptives, probenecid, ranitidine and glibenclamide. In in vitro studies, moxifloxacin does not inhibit the isoenzymes CYP3A4, CYP2D6, CYP2C9 or CYP1A2, which may indicate that moxifloxacin does not changes pharmacokinetic properties medicines, metabolized by cytochrome P450 isoenzymes.
special instructions
In patients using systemic quinolone drugs, severe, in some cases fatal, hypersensitivity reactions (anaphylaxis) were observed, sometimes immediately after taking the first dose (!). Some reactions were accompanied by collapse, loss of consciousness, Quincke's edema (including swelling of the larynx and/or face) , airway obstruction, shortness of breath, urticaria and skin itching. If the above conditions occur, resuscitation measures may be required. Long-term use of an antibiotic can lead to excessive growth of non-susceptible microorganisms, including fungi. If superinfection occurs, it is necessary to discontinue the drug and prescribe adequate therapy. Do not touch the tip of the dropper bottle to any surface to avoid contamination of the bottle and its contents. The bottle must be closed after each use. Use in pediatrics Vigamox can be used in pediatrics in children from 1 year of age in doses similar to adults. Effect on the ability to drive vehicles and operate machinery After using the drug, a temporary decrease in clarity is possible visual perception, and until it is restored, it is not recommended to drive a car or engage in activities that require increased attention and reaction.
3D images
Compound
Description of the dosage form
Transparent greenish-yellow solution.
pharmachologic effect
pharmachologic effect- broad spectrum antibacterial (bactericidal).Pharmacodynamics
Moxifloxacin is a IV generation fluoroquinolone antibacterial drug with a bactericidal effect. Shows activity against a wide range of gram-positive and gram-negative microorganisms, anaerobic, acid-fast and atypical bacteria.
The mechanism of action is associated with inhibition of topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an enzyme involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme involved in the cleavage of chromosomal DNA during bacterial cell division.
There is no cross-resistance with macrolides, aminoglycosides and tetracyclines. Cross-resistance has been reported between systemically administered moxifloxacin and other fluoroquinolones.
Moxifloxacin is active against most strains of microorganisms (as in vitro, so in vivo).
Gram-positive bacteria
Corynebacterium spp., including Corynebacterium diphtheriae;
Micrococcus luteus(including strains insensitive to erythromycin, gentamicin, tetracycline and/or trimethoprim);
Staphylococcus aureus(including strains insensitive to methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim);
Staphylococcus epidermidis
Staphylococcus haemolyticus(including strains insensitive to methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim);
Staphylococcus hominis(including strains insensitive to methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim);
Staphylococcus warneri(including strains insensitive to erythromycin);
Streptococcus mitis(including strains insensitive to penicillin, erythromycin, tetracycline and/or trimethoprim);
Streptococcus pneumoniae(including strains insensitive to penicillin, erythromycin, gentamicin, tetracycline and/or trimethoprim);
Streptococcus groups viridans(including strains that are not susceptible to penicillin, erythromycin, tetracycline and/or trimethoprim).
Gram-negative bacteria
Acinetobacter lwoffii, Haemophilus influenzae(including strains insensitive to ampicillin); Haemophilus parainfluenzae, Klebsiella spp.
Other microorganisms
Chlamydia trachomatis.
The following are the microorganisms against most of which moxifloxacin is effective: in vitro(the clinical significance of these data is unknown).
Gram-positive bacteria: Listeria monocytogenes, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus mitis, Streptococcus pyogenes, Streptococcus groups C, G, F.
Gram-negative bacteria: Acinetobacter baumannii, Acinetobacter calcoaceticus, Citrobacter freundii, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae, Proteus mirabilis, Proteus vulgaris, Pseudomonas stut zeri.
Anaerobic microorganisms: Clostridium perfringens, Fusobacterium spp., Prevotella spp., Propionibacterium acnes.
Other organisms: Chlamydia pneumoniae, Legionella pneumophila, Mycobacterium avium, Mycobacterium marinum, Mycoplasma pneumoniae.
Pharmacokinetics
When applied topically, systemic absorption of moxifloxacin occurs: C max of moxifloxacin in plasma is 2.7 ng/ml, AUC value is 45 ng h/ml. These values are approximately 1600 and 1000 times less than the Cmax and AUC after a therapeutic dose of moxifloxacin 400 mg orally. T1/2 of moxifloxacin from plasma is about 13 hours.
Indications for Vigamox ®
Bacterial conjunctivitis caused by microorganisms sensitive to moxifloxacin.
Contraindications
hypersensitivity to any of the components of the drug or other quinolones;
breastfeeding period;
children's age up to 1 year.
Use during pregnancy and breastfeeding
There is no sufficient experience with the use of the drug during pregnancy and lactation. The use of the drug during pregnancy and lactation is possible when the expected therapeutic effect exceeds the potential risk to the fetus and child.
Animal studies have shown that after oral administration of moxifloxacin with breast milk Minor amounts of the substance are excreted. However, if therapeutic doses of the drug are observed, the development of adverse reactions in infants is not expected.
Teratogenicity. In preclinical animal studies, moxifloxacin was not teratogenic at doses of 500 mg/kg/day (approximately 21.7 times the recommended daily dose for humans). However, there was a slight decrease in fetal weight and delayed development of the musculoskeletal system. At a dose of 100 mg/kg/day, an increase in the incidence of decreased growth in newborns was noted.
Side effects
During clinical trials Vigamox ® drug, reports of the following adverse reactions were received, which were classified according to the given criteria: very often (≥1/10); often (from ≥1/100 to<1/10); нечасто (от ≥1/1000 до <1/100); редко (от ≥1/10000 до <1/1000); очень редко (<1/10000). В каждой группе по частоте развития нежелательные реакции представлены в порядке убывания их степени серьезности.
From the blood and lymphatic system: rarely - decrease in Hb level.
From the nervous system: infrequently - headache; rarely - paresthesia.
From the side of the organ of vision: often - pain, irritation in the eyes; uncommon - punctate keratitis, dry eye syndrome, conjunctival hemorrhage, eye hyperemia, itching in the eyes, swelling of the eyelids, discomfort in the eyes; rarely - corneal epithelial defects, corneal disorders, conjunctivitis, blepharitis, eye swelling, conjunctival edema, blurred vision, decreased visual acuity, asthenopia, eyelid erythema.
rarely - discomfort in the nose, pharyngolaryngeal pain, sensation of a foreign body (in the throat).
From the gastrointestinal tract: infrequently - dysgeusia; rarely - vomiting.
From the liver and biliary tract: rarely - increased levels of ALT and GGT.
Post-marketing experience (frequency unknown)
From the immune system: hypersensitivity.
From the nervous system: dizziness.
From the side of the organ of vision: ulcerative keratitis, keratitis, increased lacrimation, photophobia, eye discharge.
From the side of the heart: feeling of heartbeat.
From the respiratory system, chest and mediastinal organs: dyspnea.
From the gastrointestinal tract: nausea.
For the skin and subcutaneous tissues: erythema, itching, rash, urticaria.
Interaction
The interaction of topically administered moxifloxacin with other drugs has not been studied.
Data are known for the oral dosage form of moxifloxacin: there are no clinically significant drug interactions (unlike other fluoroquinolone drugs) with theophylline, warfarin, digoxin, oral contraceptives, probenecid, ranitidine and glibenclamide.
In research in vitro moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9 or CYP1A2, which may indicate that moxifloxacin does not change the pharmacokinetic properties of drugs metabolized by cytochrome P450 isoenzymes.
Directions for use and doses
Locally. For adults and children over 1 year of age, instill 1 drop into the affected eye 3 times a day.
Typically, improvement occurs within 5 days and treatment should be continued for the next 2-3 days. If the condition does not improve after 5 days, the question of the correctness of the diagnosis and/or prescribed treatment should be raised.
The duration of treatment depends on the severity of the condition and the clinical and bacteriological course of the disease.
Overdose
If excess amounts of the drug get into your eyes, it is recommended to rinse your eyes with warm water.
special instructions
For ophthalmic use only. Not for injection. It is not allowed to administer the drug subconjunctivally or directly into the anterior chamber of the eye.
There have been reports of serious and in some cases fatal (anaphylactic) hypersensitivity reactions in patients systematically taking quinolones; In some patients, the development of a reaction was observed after the first dose. Some reactions have been accompanied by cardiovascular collapse, loss of consciousness, angioedema (including swelling of the larynx, pharynx or face), airway obstruction, dyspnea, urticaria and pruritus.
If an allergic reaction to Vigamox ® develops, you should stop using the drug. Severe acute hypersensitivity reactions to moxifloxacin may require first aid. Devices to restore oxygen supply and restore airway patency are used only for clinical indications.
Long-term use of the drug can lead to excessive growth of non-susceptible microorganisms, incl.
mushrooms In case of superinfection, it is necessary to stop using the drug and prescribe adequate therapy.
Systemic use of fluoroquinolones, including moxifloxacin, may lead to tendon inflammation and rupture, especially in elderly patients and those taking concomitant corticosteroids. Thus, when the first symptoms of tendon inflammation appear, you should stop taking the drug.
Data on the effectiveness and safety of Vigamox ® for the treatment of conjunctivitis in newborns are limited. Therefore, the use of the drug for the treatment of conjunctivitis in newborns is not recommended. Vigamox ® is not recommended for the prevention or empirical treatment of conjunctivitis, incl. gonococcal ophthalmia of newborns, due to fluoroquinolone resistance of gonococci ( Vigamox ® is not recommended for the prevention or empirical treatment of conjunctivitis, incl. Neisseria gonorrhoeae
). Patients with eye infections caused by gonococci ( ), should receive appropriate systemic treatment. Vigamox ® is not recommended for the treatment of eye infections caused by ), should receive appropriate systemic treatment. Chlamydia trachomatis
, in patients under 2 years of age, because No relevant studies have been conducted. Patients older than 2 years with eye infections caused by Vigamox ® is not recommended for the prevention or empirical treatment of conjunctivitis, incl., should receive appropriate systemic treatment. ), should receive appropriate systemic treatment..
Newborns with ophthalmia neonatorum should receive appropriate treatment based on their condition, such as systemic treatment in cases caused by gonococci (
The bottle must be closed after each use.
Use in children. Vigamox ® can be used in pediatrics in children from 1 year of age in doses similar to adults.
Vigamox (eye drops 3 mg/ml fl. 5 ml) Alcon Laboratories Inc. LLC - USA.
Characteristics: Composition of Vigamox eye drops 1 ml: - moxifloxacin hydrochloride 5.45 mg (equivalent to 5 mg moxifloxacin), excipients: sodium chloride, boric acid, hydrochloric acid and/or sodium hydroxide (to adjust pH), purified water. Pharmaceutical group: antimicrobial agent - fluoroquinolone. Pharmaceutical action: Moxifloxacin is a representative of the 4th generation of fluoroquinolone antibiotics, and acts on a wide range of Gram-positive and Gram-negative bacteria, atypical microorganisms and anaerobes. Inhibits topoisomerase 2 (DNA herase) and topoisomer 4, which are responsible for the replication, transcription, repair and recombination of bacterial DNA. The C8-methoxyl group of moxifloxacin reduces the selection of resistant strains of Gram+ bacteria, in contrast to the C8-H group found in older fluoroquinolones. The large C-7 substituent group of moxifloxacin disrupts the functioning of bacterial quinolone receptors. The bactericidal concentration of moxifloxacin is often equal to or slightly higher than the inhibitory concentration. Fluoroquinolones, including moxifloxacin, act differently from beta-lactam antibiotics, macrolides, and aminoglycosides, so they may target bacteria that are resistant to them. Organisms resistant to the above dosage forms may be sensitive to moxifloxacin. Pharmacokinetics: With topical application of VigamoxR eye drops, systemic absorption of moxifloxacin is possible. The plasma half-life is 13 hours. Indications: Topical treatment of bacterial conjunctivitis caused by the following susceptible bacteria: Gram-positive bacteria: Corynebacterium species Microbacterium species Micrococcus luteus [including strains resistant to erythromycin, gentamicin, tetracycline and/or trimethoprim] Staphylococcus aureus [including strains resistant to methicillin, erythromycin , gentamicin, ofloxacin, tetracycline and/or trimethoprim] Staphylococcus epidermidis [including strains resistant to methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim] Staphylococcus heamolyticus [including strains resistant to methicillin, erythromycin, cin, ofloxacin, tetracycline and/or trimethoprim] Staphylococcus hominis [including strains resistant to methicillin, erythromycin, gentamicin, ofloxacin, tetracycline and/or trimethoprim] Staphylococcus warneri [including strains resistant to erythromycin] Streptococcus mitis [including strains resistant to penicillin, erythromycin, tetracycline and/or trimethoprim] Streptococcus pneumoniae [including strains resistant to penicillin, erythromycin, gentamicin, tetracycline and/or trimethoprim] Streptococcus viridans [including strains resistant to penicillin, erythromycin, tetracycline and/or trimethoprim] Gram-negative bacteria: Acinetobacter species Haemophilus "alconae" Haemophilus influenzae [including strains resistant to ampicillin] Klebsiella pneumoniae [including strains resistant to ampicillin] Moraxella catarrhalis Pseudomonas aeruginosa Other microorganisms: Chlamydia trachomatis Contraindications: Hypersensitivity to any component of the drug. Dosage: Instill 1 drop into the affected eye(s) 3 times a day for 4 days. Do not touch the tip of the pipette to your eyes or any other surface to avoid contaminating the contents of the bottle. The use of VigamoxR eye drops in children and newborns is as effective and safe as when using the drug in adults and can be prescribed in the same dose as for adult patients. Side effects: Local: - blurred vision; - transient discomfort; - itching; - dry eyes; - keratitis; - subconjunctival bleeding. Systemic: When absorbed, in rare cases the following may be observed: - from the cardiovascular system: collapse of the cardiovascular system, vascular edema (including edema of the larynx, pharynx or face); - from the central nervous system: loss of consciousness, headache; - from the respiratory system: respiratory failure, pharyngitis; - from the genitourinary system: utricauria. Overdose: The limited capacity of the conjunctival sac makes it impossible to overdose with the ophthalmic drug VigamoxR. Intoxication after accidental ingestion is also excluded. Interaction: Unlike other fluoroquinolones, there are no clinically significant drug interactions observed between systemic moxifloxacin and intraconazole, theophylline, warfarin, digoxin, oral contraceptives, probenzidine, ranitidine or glyburide. Moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, or CYP1A2, indicating that it is not likely to alter the pharmacokinetic properties of drugs metabolized by cytochrome P450 isoenzymes. special instructions: As with other antibacterial agents, long-term use of the drug may cause excessive growth of insensitive organisms, including fungi. In case of superinfection, it is necessary to stop taking the drug and consider alternative methods of therapy. Risk of anaphylactic reactions Patients taking systemic quinolone drugs may have a history of severe anaphylactic reactions. If an allergic reaction develops while using moxifloxacin, you must stop taking the drug. A severe acute hypersensitivity reaction to moxifloxacin or any other component of the drug may require emergency treatment. According to clinical indications, oxygen is used and artificial respiration is performed. Pregnancy VigamoxR should be prescribed to pregnant women only if the expected benefit from its use significantly outweighs the potential risk to the fetus. Lactation Since it is unknown whether moxifloxacin passes into breast milk, VigamoxR should be administered with caution to nursing mothers. Contact lenses If symptoms of bacterial conjunctivitis are present, the patient should be advised not to wear contact lenses until completely cured. Features of the effect of the drug on the ability to drive a vehicle or operate potentially dangerous machinery As with other eye drops, after instillation, temporary blurred vision or other visual disturbances may occur, which may negatively affect the ability to drive a vehicle or other potentially dangerous machinery. In this case, you need to wait some time until your vision is restored.
Last time persecute many people.
But not everyone knows that even minor illnesses need to be treated on time so that there are no complications later.
Before using the drug need to be sure to consult with your doctor.
If there are contraindications to Vigamox, it is better to choose another drug more suitable for treatment.
Composition and features of dispensing from pharmacies
Need to know! The main active ingredient in these drops is moxifloxation hydrochloride.
But in addition to it, the medicine also contains auxiliary components:
- sodium hydrochloride;
- boric acid;
- hydrochloric acid;
- distilled water.
The drops represent absolutely clear solution, distributed in dropper bottles of 3 and 5 ml.
Most pharmacies dispense the drug only with a doctor's prescription.
Storage conditions and periods
Best before date medications is 2 years when packaged.
After opening, the medicine should be used within one month.
Keep Vigamox drops needed at temperatures from 2 to 25° Celsius. Avoid high humidity and do not give the drug to children.
Analogs
Need to know! There are several drugs with similar effects that can replace Vigamox:
It is not recommended to select an analogue for yourself. It is better to consult a doctor on this issue so as not to harm the body.
Average price in Russia for Vigamox
average price for one bottle of Vigamox drops with a volume of 5 ml is 200 rubles.
special instructions
Do not exceed the dosage. If you exceed the dose of drops, you should immediately rinse your eyes with warm, clean water.
The drug “Vigamox” is a modern medicine. They are used as eye drops in the treatment of most ophthalmic infections, and are also included in combination with other medications during eye surgeries.
The medicine has a wide range of effects and high efficiency. Vigamox drops are well tolerated by patients, which is why they are prescribed to children along with adults.
In this article we will look at why doctors prescribe Vigamox, including instructions for use, analogues and prices for this drug in pharmacies. Real REVIEWS of people who have already used Vigamox drops can be read in the comments.
Composition and release form
Vigamox is available in the form of eye drops in plastic dropper bottles of 3 and 5 ml. There is one bottle in a cardboard box.
The active component of Vigamox is moxifloxacin hydrochloride; excipients include: boric acid, sodium hydrochloride, hydrochloric acid, purified water.
Clinical and pharmacological group: antibacterial drug of the fluoroquinolone group for topical use in ophthalmology.
What does Vigamox help with?
Vigamox eye drops are indicated for local etiotropic treatment of infectious and inflammatory processes of the eye, aimed at destroying bacteria, in particular for the treatment of bacterial conjunctivitis (inflammation of the conjunctiva), in the complex therapy of blepharitis (inflammation of the eyelid).
pharmachologic effect
According to the instructions, Vigamox acts against a variety of gram-negative and gram-positive bacteria, anaerobes, acid-fast and atypical bacteria: Mycoplasma spp., Legionella spp., Chlamydia spp. It also effectively fights strains of microorganisms that are resistant to macrolides and resistant to beta-lactam antibiotics.
Instructions for use
For topical ophthalmic use only.
- According to the instructions for use of Vigamox, it is prescribed to adults and children over 1 year of age by instilling 1 drop into the affected eye 3 times a day. Typically, improvement occurs within 5 days and treatment should be continued for the next 2-3 days.
If the condition does not improve after 5 days, the question of the correctness of the diagnosis and/or prescribed treatment should be raised.
The duration of treatment depends on the severity of the condition and the clinical and bacteriological course of the disease.
Contraindications
The drug is not prescribed to children under one year of age, women during breastfeeding, or patients with hypersensitivity to the components of the drug or other quinolones.
Side effects
There are reviews of Vigamox that confirm the development of some side effects due to the use of drops. These include: dry eyes, itching, keratitis, blurred vision, subconjunctival bleeding.
In rare cases, reviews of Vigamox indicate symptoms such as loss of consciousness, collapse, pharyngitis, Quincke's edema, respiratory failure, urticaria, headache and vascular edema.
If the above side effects occur, you should stop treatment with Vigamox and consult a doctor.
Analogues of Vigamox
Structural analogues of the active substance:
- Avelox;
- Aquamox;
- Moximac;
- Moxin;
- Moxyspenser;
- Moxifloxacin;
- Moxifloxacin hydrochloride;
- Moxifur;
- Plevilox;
- Rotomox;
- Hynemox.
Attention: the use of analogues must be agreed with the attending physician.
Prices
The average price of VIGAMOX, drops in pharmacies (Moscow) is 220 rubles.
Conditions for dispensing from pharmacies
On prescription.
Levomycetin eye drops: instructions for use, prices and analogues
Vitabact eye drops - instructions, reviews, analogues
Sulfacyl sodium eye drops: instructions, reviews, analogues